RaySearch Laboratories AB (publ) Year-end Report 2011

JANUARY 1 – DECEMBER 31, 2011

• Net sales for the year amounted to SEK 126.1 M (117.7)
• Profit after tax totaled SEK 17.0 M (28.9) and earnings per share amounted to SEK 0.50 (0.84)
• Operating profit totaled SEK 27.6 M (39.9)
• Cash flow amounted to negative SEK 46.2 (-5.0)
• RaySearch licensed groundbreaking technology from Princess Margaret Hospital in March
• RaySearch became involved in a US patent dispute in May
• First patient treated with a plan from RayStation® in September in the US and the first patient in Europe was treated in December
• Sales organizations established in the US and Europe
• Distribution agreements secured for Italy, China and South Korea
• A total of nine orders for RayStation® received from Canada, the Netherlands, Switzerland and the US
• The Board of Directors proposes that no dividend will be paid for 2011

AFTER THE END OF THE PERIOD

• The first complete version of RayStation® was released in January

” Financially, RayStation® started to contribute significant revenues in conjunction with its installation at several customers at the end of the year. From a revenue viewpoint, the fourth quarter was the best ever with SEK 45.8 M in revenues compared with SEK 34.8 M in the fourth quarter 2010”, says Johan Löf, President of RaySearch.

” In 2011, we successfully implemented a strategic shift in which we went from complete dependence on partners to establishing opportunities to sell directly to clinics in parallel with our partner-based business model. We have noted strong interest for RayStation® and a large number of business discussions are ongoing in North America, Europe and Asia so we hope to finalize several important deals in 2012, ”, concludes Johan Löf.

ABOUT RAYSEARCH
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are mainly sold through license agreements with leading partners such as Philips, Nucletron, IBA Dosimetry, Varian, Accuray and Siemens. To date, 15 products have been launched through partners and RaySearch’s software is used at some 1,800 clinics in more than 30 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm

For more information about RaySearch, visit www.raysearchlabs.com.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
Johan Löf, President
Tel: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com

Tags: